First-quarter 2023 XIAFLEX ® revenues were $97 million, a 3% decrease compared to first-quarter 2022 driven by channel inventory destocking. This change was primarily due to a decrease in Supprelin ® LA mainly driven by lower average net selling price as a result of business mix. Specialty Products revenues decreased 5% to $142 million in first-quarter 2023 compared to $149 million in first-quarter 2022. These results were primarily driven by lower interest and adjusted operating expenses, which were partially offset by decreased revenues.įirst-quarter 2023 Branded Pharmaceuticals segment revenues were $198 million, a decrease of 4% compared to $205 million during first-quarter 2022. Adjusted diluted net income per share from continuing operations in first-quarter 2023 was $0.82 compared to $0.66 in first-quarter 2022. These results were primarily due to lower interest expenses as a result of the Chapter 11 filing as well as lower operating expenses, asset impairment and litigation-related charges, partially offset by decreased revenues and increased expenses related to the Chapter 11 reorganization process.Īdjusted income from continuing operations in first-quarter 2023 was $193 million compared to $156 million in first-quarter 2022. Reported diluted net loss per share from continuing operations in first-quarter 2023 was $0.01 compared to $0.28 in first-quarter 2022. Reported loss from continuing operations in first-quarter 2023 was $3 million compared to $65 million in first-quarter 2022. This decrease was primarily attributable to decreased revenues from the Sterile Injectables segment, partially offset by increased revenues from the Generic Pharmaceuticals segment. Total revenues were $515 million in first-quarter 2023, a decrease of 21% compared to $652 million in first-quarter 2022. Refer to note (13) in the 'Notes to the Reconciliations of GAAP and Non-GAAP Financial Measures' section below for additional discussion. Refer to the 'Supplemental Financial Information' section below for reconciliations of certain non-GAAP financial measures to the most directly comparable GAAP financial measures.Įffective January 1, 2022, these non-GAAP financial measures now include acquired in-process research and development charges which were previously excluded under Endo's legacy non-GAAP policy.

The information presented in the table above includes non-GAAP financial measures such as Adjusted Income from Continuing Operations, Adjusted Diluted Weighted Average Shares, Adjusted Diluted Net Income per Share from Continuing Operations and Adjusted EBITDA. In the case of Adjusted Diluted Weighted Average Shares, Adjusted Income from Continuing Operations is used in determining whether to include such dilutive impact. Reported Diluted Net Loss per Share from Continuing Operations is computed based on weighted average shares outstanding and, if there is income from continuing operations during the period, the dilutive impact of ordinary share equivalents outstanding during the period.

Endo international plc founder